An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

This study is testing a new cell therapy called OriV508 in people with relapsed or treatment-resistant blood cancers, including multiple myeloma and aggressive B-cell lymphoma. **You may be eligible if...** - You are between 18 and 75 years old and in good general health - You have been diagnosed with multiple myeloma or aggressive B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment - For myeloma: you have already tried at least three prior treatments - For lymphoma: your cancer has come back after a stem cell transplant or you are not eligible for one - Your cancer is measurable on scans and you have a life expectancy of at least 12 weeks **You may NOT be eligible if...** - You have active infections, autoimmune disease, or significant organ problems - You have had certain prior therapies that would disqualify you based on timing - Your overall health is too poor to safely receive the treatment Talk to your doctor to see if this trial is right for you.